Vaborbactam, also known as RPX7009, is a potent and selective beta-lactamase inhibitor. Vaborbactam shows broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains. Combined with a carbapenem, Vaborbactam is a promising product for the treatment of multidrug resistant Gram-negative bacteria. For recent consecutive strains of Bacteroides species, the MIC(90) for biapenem-RPX7009 was 1 μg/ml, with a MIC(90) of 4 μg/ml for meropenem.
Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N. Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. Journal of Medicinal Chemistry. Volume 58. Issue 9. Pages 3682-3692. Journal. (2015)
Dudley, Michael N.; Hecker, Scott; Rodny, Olga. Methods of treating bacterial infections. Assignee Rempex Pharmaceuticals, Inc., USA. WO 2013122888. (2013)
Hecker, Scott; Boyer, Serge. (Assignee: Rempex Pharmaceuticals, Inc., USA). Synthesis of boronate salts and uses thereof . WO 2015171430 (2015).
